Breast cancer treatment and adverse cardiac events: What are the molecular mechanisms?

Cardiology (Switzerland)

Volumn 122, Issue 4, 2012, Pages 253-259

  Roca Alonso, Laura ^a   Pellegrino, Loredana ^a   Castellano, Leandro ^a   Stebbing, Justin ^a  

^a HAMMERSMITH HOSPITAL   (United Kingdom)

Author keywords

Chemotherapy; Doxorubicin; Heart failure; MicroRNA; Tyrosine kinase inhibitors

Indexed keywords

ANTHRACYCLINE; ANTINEOPLASTIC AGENT; ANTIOXIDANT; CASPASE 9; CATALASE; CYTOCHROME C; DAUNORUBICIN; DNA TOPOISOMERASE (ATP HYDROLYSING); DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR 4; GLUTATHIONE PEROXIDASE; HELICASE; HYDROGEN PEROXIDE; LAPATINIB; MESSENGER RNA; MICRORNA; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; NEU DIFFERENTIATION FACTOR; PROTEIN P53; PROTEIN TYROSINE KINASE INHIBITOR; REACTIVE OXYGEN METABOLITE; SUPEROXIDE; SUPEROXIDE DISMUTASE; TRASTUZUMAB;

APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CELL; CANCER PROGNOSIS; CARDIOMYOPATHY; CARDIOTOXICITY; CELL CYCLE ARREST; CYTOTOXICITY; DNA STRAND BREAKAGE; DOSE RESPONSE; DRUG EFFICACY; DRUG MECHANISM; EARLY DIAGNOSIS; ENZYME INHIBITION; GENE EXPRESSION REGULATION; HEART DEVELOPMENT; HEART FAILURE; HEART FUNCTION; HEART PROTECTION; HUMAN; MOLECULARLY TARGETED THERAPY; NONHUMAN; OXIDATIVE STRESS; PATIENT MONITORING; PRIORITY JOURNAL; SIGNAL TRANSDUCTION;

ANTIBIOTICS, ANTINEOPLASTIC; BREAST NEOPLASMS; DOXORUBICIN; FEMALE; HEART DISEASES; HUMANS; MICRORNAS; MOLECULAR TARGETED THERAPY; MYOCYTES, CARDIAC; OXIDATIVE STRESS; PROTEIN-TYROSINE KINASES; REACTIVE OXYGEN SPECIES; RECEPTOR, ERBB-2;

EID: 84865060042     PISSN: 00086312     EISSN: 14219751     Source Type: Journal    
DOI: 10.1159/000339858     Document Type: Article

References (72)

1. World Health Organization website. www. who.ing/cancer (May 2012).
2. Cancer Research UK website. www.cancer-researchuk.org (May 2012).
3. Minotti G, et al: Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol Rev 2004; 56: 185-229. (Pubitemid 38720829)
4. Lefrak EA, et al: A clinicopathologic analysis of adriamycin cardiotoxicity. Cancer 1973; 32:302-314.
5. Buja LM, et al: Cardiac ultrastructural changes induced by daunorubicin therapy. Cancer 1973; 32:771-788.
6. Steinherz LJ, et al: Cardiac toxicity 4 to 20 years after completing anthracycline therapy. JAMA 1991; 266: 1672-1677.
7. David AG: A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics adria-mycin and daunorubicin. Biochem Pharmacol 1999; 57: 727-741.
8. Goodman MF, Bessman MJ, Bachur NR: Adriamycin and daunorubicin inhibition of mutant T4 DNA polymerases. Proc Natl Acad Sci USA 1974; 71: 1193-1196.
9. Momparler RL, et al: Effect of adriamycin on DNA, RNA, and protein synthesis in cell-free systems and intact cells. Cancer Res 1976; 36:2891-2895.
10. Davies KJ, Doroshow JH: Redox cycling of anthracyclines by cardiac mitochondria. 1. Anthracycline radical formation by NADH dehydrogenase. J Biol Chem 1986; 261: 3060-3067. (Pubitemid 17204909)
11. Fornari FA, et al: Interference by doxorubi-cin with DNA unwinding in MCF-7 breast tumor cells. Mol Pharmacol 1994; 45: 649-656. (Pubitemid 24139191)
12. Bachur NR, et al: Antihelicase action of DNA-binding anticancer agents: relationship to guanosine-cytidine intercalator binding. Mol Pharmacol 1993; 44: 1064-1069. (Pubitemid 23344977)
13. D'Arpa P, Liu LF: Topoisomerase-targeting antitumor drugs. Biochim Biophys Acta 1989; 989: 163-177. (Pubitemid 20008970)
14. Skladanowski A, Konopa J: Adriamycin and daunomycin induce programmed cell death (apoptosis) in tumour cells. Biochem Pharmacol 1993; 46: 375-382. (Pubitemid 23239986)
15. Ling YH, et al: Cell cycle-dependent cytotox-icity, G2/M phase arrest, and disruption of p34cdc2/cyclin B1 activity induced by doxo-rubicin in synchronized P388 cells. Mol Pharmacol 1996; 49: 832-841.
16. Singal PK, Iliskovic N: Doxorubicin-induced cardiomyopathy. N Engl J Med 1998; 339: 900-905. (Pubitemid 28446849)
17. Takemura G, Fujiwara H: Doxorubicin-in-duced cardiomyopathy: from the cardiotoxic mechanisms to management. Prog Cardio-vasc Dis 2007; 49:330-352. (Pubitemid 46295436)
18. Hjalmarson A, Waagstein F: The role of [beta]-blockers in the treatment of cardio-myopathy and ischaemic heart failure. Drugs 1994; 47:31-40. (Pubitemid 24190903)
19. Alberts DS, et al: Efficacy and safety of lipo-somal anthracyclines in phase I/II clinical trials. Semin Oncol 2004; 31(suppl 13):53-90. (Pubitemid 40023242)
20. Robert NJ, et al: The role of the liposomal anthracyclines and other systemic therapies in the management of advanced breast cancer. Semin Oncol 2004; 31(suppl 13): 106-146. (Pubitemid 40023244)
21. Menna P, et al: Anthracycline cardiotoxicity. Expert Opin Drug Safe 2012; 11:S21-S36.
22. Burke PJ, Koch TH: Design, synthesis, and biological evaluation of doxorubicin-formal-dehyde conjugates targeted to breast cancer cells. J Med Chem 2004; 47:1193-1206. (Pubitemid 38229121)
23. Doroshow JH: Effect of anthracycline antibiotics on oxygen radical formation in rat heart. Cancer Res 1983; 43:460-472. (Pubitemid 13193830)
24. Velez JM, et al: p53 regulates oxidative stress-mediated retrograde signaling: a novel mechanism for chemotherapy-induced cardiac injur y. PLoS ONE 2011; 6:e18005.
25. Yen HC, et al: The protective role of manganese superoxide dismutase against adriamy-cin-induced acute cardiac toxicity in trans-genic mice. J Clin Invest 1996; 98:1253-1260.
26. Doroshow JH, Locker GY, Myers CE: Enzymatic defenses of the mouse heart against reactive oxygen metabolites: alterations produced by doxorubicin. J Clin Invest 1980; 65: 128-135. (Pubitemid 10214339)
27. Siveski-Iliskovic N, Kaul N, Singal P: Probu-col promotes endogenous antioxidants and provides protection against adriamycin-in-duced cardiomyopathy in rats. Circulation 1994; 89:2829-2835. (Pubitemid 24173705)
28. Kalyanaraman B, et al: Doxorubicin-in-duced apoptosis: implications in cardiotox-icity. Mol Cell Biochem 2002; 234-235: 119-124.
29. Singal PK, et al: Combination therapy with probucol prevents adriamycin-induced car-diomyopathy. J Mol Cell Cardiol 1995; 27: 1055-1063.
30. Green PS, Leeuwenburgh C: Mitochondrial dysfunction is an early indicator of doxoru-bicin-induced apoptosis. Biochim Biophys Acta 2002; 1588:94-101.
31. Childs AC, et al: Doxorubicin treatment in vivo causes cytochrome c release and cardio-myocyte apoptosis, as well as increased mi-tochondrial efficiency, superoxide dis-mutase activity, and Bcl-2:Bax ratio. Cancer Res 2002; 62: 4592-4598.
32. Feridooni T, et al: Cardiomyocyte specific ablation of p53 is not sufficient to block doxorubicin induced cardiac fibrosis and associated cytoskeletal changes. PLoS One 2011; 6:e22801.
33. Slamon D, et al: Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987; 235: 177-182. (Pubitemid 17231334)
34. Slamon D, et al: Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 1989; 244:707-712. (Pubitemid 19147683)
35. Olayioye MA, et al: The ErbB signaling network: receptor heterodimerization in development and cancer. EMBO J 2000; 19: 3159-3167. (Pubitemid 30428195)
36. Force T, Krause DS, Van Etten RA: Molecular mechanisms of cardiotoxicity of tyrosine kinase inhibition. Nat Rev Cancer 2007; 7: 332-344. (Pubitemid 46652481)
37. Burris HA, et al: Phase I safety, pharmacoki-netics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carcinomas. J Clin Oncol 2005; 23: 5305-5313.
38. Slamon DJ, et al: Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001; 344: 783-792. (Pubitemid 32222155)
39. Azim H, Azim HA Jr, Escudier B: Trastu-zumab versus lapatinib: the cardiac side of the story. Cancer Treat Rev 2009; 35: 633-638.
40. Perez EA, et al: Cardiac safety of lapatinib: pooled analysis of 3689 patients enrolled in clinical trials. Mayo Clin Proc 2008; 83:679-686. (Pubitemid 351810568)
41. Wysocki P, Wysocki H: Cardiovascular complications associated with biological therapies for breast cancer. Expert Opin Biol Ther 2008; 8: 1551-1559.
42. Grazette LP, et al: Inhibition of ErbB2 causes mitochondrial dysfunction in cardiomyo-cytes: implications for herceptin-induced cardiomyopathy. J Am Coll Cardiol 2004; 44: 2231-2238. (Pubitemid 39576044)
43. Meyer D, Birchmeier C: Multiple essential functions of neuregulin in development. Nature 1995; 378: 386-390.
44. Zhao Y-Y, et al: Neuregulins promote survival and growth of cardiac myocytes. J Biol Chem 1998; 273: 10261-10269.
45. Lee K-F, et al: Requirement for neuregulin receptor erbB2 in neural and cardiac development. Nature 1995; 378: 394-398.
46. Negro A, Brar BK, Lee KF: Essential roles of Her2/erbB2 in cardiac development and function. Recent Prog Horm Res 2004; 59: 1-12. (Pubitemid 41327144)
47. Rohrbach S, et al: Neuregulin receptors erbB2 and erbB4 in failing human myocardium. Basic Res Cardiol 2005; 100:240-249.
48. Jiang Z, Zhou M: Neuregulin signaling and heart failure. Curr Heart Fail Rep 2010; 7:42-47.
49. Sawyer DB, Caggiano A: Neuregulin-1fS for the treatment of systolic heart failure. J Mol Cell Cardiol 2011; 51: 501-505.
50. Timolati F, et al: Neuregulin-1 beta attenuates doxorubicin-induced alterations of excitation-contraction coupling and reduces oxidative stress in adult rat cardiomyocytes. J Mol Cell Cardiol 2006; 41:845-854. (Pubitemid 44635571)
51. Lewis B, Burge C, Bartel D: Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are mi-croRNA targets. Cell 2005; 120:15-20. (Pubitemid 40094598)
52. Bartel D: MicroRNAs: target recognition and regulatory functions. Cell 2009; 136: 215-233.
53. Bartel D: MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004; 116: 281-297.
54. Creemers EE, Wilde AA, Pinto YM: Heart failure: advances through genomics. Nat Rev Genet 2011; 12:357-362.
55. Souders CA, Bowers SLK, Baudino TA: Cardiac fibroblast. Circ Res 2009; 105:1164-1176.
56. Kang PM, Izumo S: Apoptosis and heart failure: a critical review of the literature. Circ Res 2000; 86:1107-1113. (Pubitemid 30396034)
57. da Costa Martins PA, et al: Conditional dicer gene deletion in the postnatal myocardium provokes spontaneous cardiac remodeling. Circulation 2008; 118:1567-1576.
58. Farh KK, et al: The widespread impact of mammalian microRNAs on mRNA repression and evolution. Science 2005; 310: 1817-1821. (Pubitemid 41814382)
59. Bernstein E, et al: Dicer is essential for mouse development. Nat Genet 2003; 35: 215-217. (Pubitemid 37363172)
60. van Rooij E: A signature pattern of stress-responsive microRNAs that can evoke cardiac hypertrophy and heart failure. Proc Natl Acad Sci USA 2006; 103: 18255-18260. (Pubitemid 44871645)
61. Thum T, et al: MicroRNAs in the human heart. Circulation 2007; 116: 258-267.
62. Ikeda S, et al: Altered microRNA expression in human heart disease. Physiol Genom 2007; 31:367-373. (Pubitemid 350127777)
63. Yang B, et al: The muscle-specific microRNA miR-1 regulates cardiac arrhythmogenic potential by targeting GJA1 and KCNJ2. Nat Med 2007; 13: 486-491. (Pubitemid 46559834)
64. Kumarswamy R, et al: SERCA2a gene therapy restores microRNA-1 expression in heart failure via an Akt/FoxO3A-dependent pathway. Eur Heart J 2012; 33:1067-1075.
65. Dong D-L, et al: Reciprocal repression between microRNA-133 and calcineurin regulates cardiac hypertrophy. Hypertension 2010; 55:946-952.
66. Care A, et al: MicroRNA-133 controls cardiac hyper trophy. Nat Med 2007; 13: 613-618. (Pubitemid 46828487)
67. van Rooij E, et al: Control of stress-dependent cardiac growth and gene expression by a microR NA. Science 2007; 316: 575-579. (Pubitemid 46683138)
68. van Rooij E, et al: Dysregulation of micro-RNAs after myocardial infarction reveals a role of miR-29 in cardiac fibrosis. Proc Natl Acad Sci USA 2008; 105: 13027-13032.
69. Wang J-X, et al: miR-499 regulates mito-chondrial dynamics by targeting calcineurin and dynamin-related protein-1. Nat Med 2011; 17: 71-78.
70. Horie T, et al: Acute doxorubicin cardiotox-icity is associated with miR-146a-induced inhibition of the neuregulin-ErbB pathway. Cardiovasc Res 2010; 87:656-664.
71. Creemers EE, Tijsen AJ, Pinto YM: Circulating microRNAs. Circ Res 2012; 110:483-495.
72. van Rooij E, Marshall WS, Olson EN: Toward microRNA-based therapeutics for heart disease. Circ Res 2008; 103:919-928.